# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Neutral and maintains $22 price target.
Patients treated with TTFields therapy and BSC exhibited a median time to intracranial progression of 21.9 months compared to 1...
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target fro...